Mariner
BCAX

Mariner’s Bicara Therapeutics BCAX Stock Holding History

Mariner’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
53,112
-1,925
-3% -$43K ﹤0.01% 1637
2026
Q1 		$1.09M Sell
55,037
-9,525
-15% -$164K ﹤0.01% 1904
2025
Q4 		$1.09M Buy
64,562
+1,902
+3% +$32.5K ﹤0.01% 1894
2025
Q3 		$989K Buy
62,660
+50,223
+404% +$562K ﹤0.01% 1914
2025
Q2 		$116K Buy
+12,437
New +$148K ﹤0.01% 3212

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner's BCAX Position: Q2 2026 in Review

Mariner reduced its Bicara Therapeutics (BCAX) stake by 3.5% in Q2 2026, selling an estimated $43K and leaving 53,112 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Mariner first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Mariner held 53,112 shares of Bicara Therapeutics worth $1.58M as of Q2 2026.
  • Mariner sold 1,925 Bicara Therapeutics shares in Q2 2026, an estimated $43K.
  • Bicara Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1637 holding.
  • Mariner first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.